Home> Products> Inhibitors> Eldecalcitol-CAS 104121-92-8
price inquiry for CAS:104121-92-8, Product:Eldecalcitol

Eldecalcitol CAS: 104121-92-8

Category: Inhibitors
Product Name: Eldecalcitol
Cat No: I000240
CAS No: 104121-92-8
Synonyms: (1S,2S,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-2-(3-hydroxypropoxy)-4-methylidenecyclohexane-1,3-diol
Molecular Formula: C30H50O5
Molecular Weight: 490.72
SMILES: CC(C)(O)CCC[C@@H](C)[C@H]([C@]1(CCC/2)C)CC[C@@]1([H])C2=C\C=C3C[C@H](O)[C@H](OCCCO)[C@@H](O)C\3=C
InChI: None
InChIKey: None
Solubility: 10 mM in DMSO
Target: VD/VDR
Storage: Store at -20°C
CAS 104121-92-8,Eldecalcitol
  • Description

Eldecalcitol (ED-71; 2.beta.-(3-Hydroxypropoxy)-1.alpha.,25-dihydroxyvitamin D3) is an analog of 1,25-dihydroxyvitamin D3 that improves bone mineral density.
IC50 value:
Target: Vd analog
Eldecalcitol (ED-71; 2.beta.-(3-Hydroxypropoxy)-1.alpha.,25-dihydroxyvitamin D3) is more efficacious than alfacalcidol in preventing vertebral and wrist fractures in osteoporotic patients with vitamin D sufficiency, with a safety profile similar to alfacalcidol.

  • Spec

Appearance:Solid powder
Purity: > 98%

  • References


1:Effect of osteoporosis medication on changes in bone mineral density and bone turnover markers after 24-month administration of daily teriparatide: comparison among minodronate, raloxifene, and eldecalcitol. Nakatoh S.J Bone Miner Metab. 2017 Mar 14. doi: 10.1007/s00774-017-0829-4. [Epub ahead of print] PMID: 28293779
2:Combined use of ibandronate and eldecalcitol in postmenopausal Japanese women with osteoporosis. Takada J, Wada H, Iba K, Sasaki K, Dohke T, Kanaya K, Yoshizaki T, Yamashita T.J Orthop Surg (Hong Kong). 2016 Dec;24(3):362-366. PMID: 28031507 Free Article
3:A vitamin D analogue, eldecalcitol, enhances expression of fast myosin heavy chain subtypes in differentiated C2C12 myoblasts. Saito H, Kishimoto KN, Mori Y, Okuno H, Tanaka M, Itoi E.J Orthop Sci. 2017 Mar;22(2):345-350. doi: 10.1016/j.jos.2016.12.005. Epub 2016 Dec 23. PMID: 28017710
4:Selective estrogen receptor modulators and the vitamin D analogue eldecalcitol block bone loss in male osteoporosis. Sato Y, Tando T, Morita M, Miyamoto K, Kobayashi T, Watanabe R, Oike T, Matsumoto M, Nakamura M, Miyamoto T.Biochem Biophys Res Commun. 2017 Jan 22;482(4):1430-1436. doi: 10.1016/j.bbrc.2016.12.053. Epub 2016 Dec 11. PMID: 27974229
5:Histochemical examination of systemic administration of eldecalcitol combined with guided bone regeneration for bone defect restoration in rats. Han X, Du J, Liu D, Liu H, Amizuka N, Li M.J Mol Histol. 2017 Feb;48(1):41-51. doi: 10.1007/s10735-016-9705-0. Epub 2016 Nov 23. PMID: 27882438
6:The safety and effectiveness profile of eldecalcitol in a prospective, post-marketing observational study in Japanese patients with osteoporosis: interim report. Saito H, Kakihata H, Nishida Y, Yatomi S, Nihojima S, Kobayashi Y, Tabata H, Nomura M.J Bone Miner Metab. 2016 Oct 3. [Epub ahead of print] PMID: 27699492
7:Comparison of the effects of eldecalcitol with either raloxifene or bisphosphonate on serum tartrate resistant acid phosphatase-5b, a bone resorption marker, in postmenopausal osteoporosis. Takada J, Ikeda S, Kusanagi T, Mizuno S, Wada H, Iba K, Yoshizaki T, Yamashita T.Clin Cases Miner Bone Metab. 2016 Jan-Apr;13(1):25-8. doi: 10.11138/ccmbm/2016.13.1.025. Epub 2016 May 11. PMID: 27252739 Free PMC Article
8:Erratum: Treatment of osteoporosis with eldecalcitol, a new vitamin D analog: a comprehensive review and meta-analysis of randomized clinical trials [Corrigendum]. [No authors listed]Drug Des Devel Ther. 2016 Feb 15;10:697. doi: 10.2147/DDDT.S105820. eCollection 2016. No abstract available. PMID: 26929600 Free PMC Article
9:Treatment of osteoporosis with eldecalcitol, a new vitamin D analog: a comprehensive review and meta-analysis of randomized clinical trials. Xu Z, Fan C, Zhao X, Tao H.Drug Des Devel Ther. 2016 Jan 28;10:509-17. doi: 10.2147/DDDT.S84264. eCollection 2016. Review. Erratum in: Drug Des Devel Ther. 2016;10:697. PMID: 26869769 Free PMC Article
10:Further significant effects of eldecalcitol on bone resorption markers and bone mineral density in postmenopausal osteoporosis patients having undergone long-term bisphosphonate treatment. Iba K, Sonoda T, Takada J, Dohke T, Yamashita T.J Bone Miner Metab. 2017 Mar;35(2):171-176. doi: 10.1007/s00774-016-0738-y. Epub 2016 Jan 30. PMID: 26832388


price inquiry for CAS:104121-92-8, Product:Eldecalcitol